Our new products

Esozol. A new product in the company's line for the treatment of upper gastrointestinal bleeding.

Bleeding into the lumen of the gastrointestinal tract (GIT) is often an acute and life-threatening complication of various diseases and injuries of internal organs. There are about 116 diseases that sometimes cause gastrointestinal bleeding (GI bleeding), while 5 diseases (peptic ulcer, acute ulcers and erosion, tumours, Mallory-Weiss syndrome, portal hypertension) account for over 90% of all GI causes, the rest the reasons are extremely rare. The incidence of GI bleedings in the gastrointestinal tract and associated hospitalization was 103 - 172/100.000 adults per year in the UK in the 1990s, and 61 - 78/100.000 adults in the USA in 2009-2012, and for comparison – 1 per 1000 population in Ukraine. However, over the past 10 years, the cases requiring hospital admissions have been reduced by 21-23% due to the reduced incidence of peptic ulcer disease bleedings (and bleedings caused by "gastritis"). Probably it happens due to the reduced prevalence of H. pylori and the increased use of antisecretory drugs.

The mortality rate ranges from 1.9-2.5% (according to UK and US databases) while large observational cohort studies in Europe show a higher mortality rate of about 10%. For comparison, the overall mortality rate for GI bleeding is about 3.1%in Kiev while in Ukraine as a whole – 8.5%.

The main diagnostic method for GI bleeding is esophagogastroduodenoscopy. The main treatment method is endoscopic haemostasis performed by one of four methods, such as application methods, heat therapy, endoscopic injection therapy and mechanical haemostasis. Each method has its own pros and cons. However, even after successful endoscopic haemostasis, which is noted in 90% of cases, the risk of re-bleeding still remains at a fairly high level and is noted in 25% of cases within 72 hours after endoscopic haemostasis. Therefore, there is an urgent recommendation for the use of proton pump inhibitors (PPIs) both before and after endoscopy in the European Society of Endoscopic Gastroenterologists Guidelines (Europe, ESGE, 2015).  Moreover, it has been proven that the risk of re-bleeding and mortality reduce in high-risk patients, after a successful endoscopic procedure for the administration of high doses of PPIs (80 mg IV bolus followed by continuous infusion of 8 mg/hour for 72 hours).

Ananta Medicare has registered (Registration certificate: UA/14382/01/01 No.1729 dated 30.07.2020) and is going to promote a modern fourth-generation PPI esomeprazole named Esozol. Esozol (esomeprazole) is released in 40 mg vials. It is user-friendly in accordance with the European Society of Endoscopic Gastroenterologists Guidelines.